Get the Stockscreener App
12.75
13.26%
-1.9499
Pre-market:
14.19
1.4399
+11.29%
Eloxx Pharmaceuticals Inc stock is traded at $12.75, with a volume of 22,375.
It is down -13.26% in the last 24 hours and down -69.80% over the past month.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
See More
Previous Close:
$14.70
Open:
$15.06
24h Volume:
22,375
Relative Volume:
6.13
Market Cap:
$43.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-56.28%
1M Performance:
-69.80%
6M Performance:
-75.18%
1Y Performance:
-68.68%
1-Day Range:
$12.00
$15.75
1-Week Range:
$8.20
$17.50
52-Week Range:
$8.20
$17.50
Eloxx Pharmaceuticals Inc Stock (ELOX) Company Profile
Name
Eloxx Pharmaceuticals Inc
Sector
Industry
Phone
781-577-5300
Address
P.O. BOX 274, ARLINGTON
Compare ELOX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELOX
Eloxx Pharmaceuticals Inc
|
12.75 | 50.51M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eloxx Pharmaceuticals Inc Stock (ELOX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Initiated | B. Riley Securities | Buy |
| Jun-11-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-06-19 | Initiated | Janney | Buy |
| Dec-24-18 | Initiated | H.C. Wainwright | Neutral |
| Jul-03-18 | Initiated | Citigroup | Buy |
View All
Eloxx Pharmaceuticals Inc Stock (ELOX) Latest News
Invus-led group holds 9.99% of Eloxx (ELOX) via shares and warrants - Stock Titan
ELOX Technical Analysis & ETF Price Forecast - Intellectia AI
symbol__ Stock Quote Price and Forecast - CNN
ELOX Price Today: Eloxx Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Eloxx Pharma (ELOX) Stock Analysis Report | Financials & Insights - Benzinga
Eloxx (NASDAQ: ELOX) CEO receives 328,833 performance-based stock options - Stock Titan
Eloxx Pharmaceuticals (ELOX) director receives 13,587 stock options grant - Stock Titan
Eloxx (ELOX) director Steven Rubin receives 4,018 stock options at $11 strike - Stock Titan
Eloxx (ELOX) director Stephen Webster receives stock options for 13,587 shares - Stock Titan
ELOX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ELOX Technical Analysis & Stock Price Forecast - Intellectia AI
ELOX PE Ratio & Valuation, Is ELOX Overvalued - Intellectia AI
ELOX News & Events - Intellectia AI
ELOX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Eloxx Pharmaceuticals, Inc.(NasdaqCM: ELOX) added to NASDAQ Composite Index - marketscreener.com
Form 424B4 Eloxx Pharmaceuticals, - StreetInsider
Eloxx Pharmaceuticals (ELOX) raises ~$66M via stock and pre‑funded warrants - Stock Titan
Eloxx Pharmaceuticals Offering Expected to Close June 10 >ELOX - Moomoo
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering - Pharmaceutical Executive
[EFFECT] Eloxx Pharmaceuticals, Inc. SEC Filing - Stock Titan
Eloxx Pharmaceuticals prices $66.0 million offering, uplists to Nasdaq - scanx.trade
Eloxx Pharmaceuticals: Shares Expected to Start Trading on Nasdaq Capital Market on June 9 >ELOX - Moomoo
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq - PR Newswire
Eloxx Pharmaceuticals Inc (ELOXD) Stock PDF (Updated: 2026/06/06) - GuruFocus
ELOX SEC FilingsEloxx Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Domicilium files Schedule 13G/A reporting 4.9% stake in Eloxx (NASDAQ: ELOX) - Stock Titan
Domicilium Real Estate Fund III LP (ELOX) swaps 1.25M shares for pre-funded warrants - Stock Titan
Total debt per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Working capital per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Book value per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Return on invested capital % of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
EBITDA per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Free cash flow per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Debt to equity ratio of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Net current asset value per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Asset turnover of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Operating cash flow per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Long term debt to total assets ratio of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
CapEx per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Long term debt to total equity ratio of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Debt to assets ratio of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Return on assets % of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Price to cash flow ratio of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
EBIT per share of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Enterprise value of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Eloxx Pharmaceuticals, Inc. Statistics – OTC:ELOXD - TradingView
Enterprise value to EBITDA ratio of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
EBITDA margin % of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Total liabilities of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Net margin % of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Total debt of Eloxx Pharmaceuticals, Inc. – OTC:ELOXD - TradingView
Eloxx Pharmaceuticals Inc Stock (ELOX) Financials Data
There is no financial data for Eloxx Pharmaceuticals Inc (ELOX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):